Welcome to our dedicated page for Eupraxia Pharmac SEC filings (Ticker: EPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eupraxia Pharmaceuticals Inc.'s SEC filings document a clinical-stage biotechnology issuer reporting current events on Form 6-K, with Form 40-F status indicated in the filings. Recent reports furnish press releases and exhibits covering the Diffusphere drug-delivery platform, EP-104GI clinical disclosures in eosinophilic esophagitis, RESOLVE trial scoring measures such as EREFS and EoEHSS, and scientific-meeting presentations.
The filings also record governance and securityholder matters, including executive medical leadership changes, annual general meeting notice materials, voting and record-date mechanics for common shares, and issuer identifiers such as CUSIP and ISIN. These disclosures frame Eupraxia's public-company record around clinical development, governance, and common-share voting matters.
Eupraxia Pharmaceuticals Inc. received an amended Schedule 13G showing that a group of related investment entities and individuals report beneficial ownership just under 10% of its common shares. Manchester Explorer, L.P. reports owning 4,597,217 shares, or 8.6% of the class, while Manchester Management entities each report 8.8%.
Individuals James E. Besser and Morgan C. Frank report beneficial ownership of 4,858,437 shares (9.1%) and 4,904,523 shares (9.2%), respectively, including both sole and shared voting and dispositive power. Most shares are held for advisory clients of Manchester Management PR, LLC, which generally do not exceed 5% ownership individually.
Eupraxia Pharmaceuticals reported encouraging new data from the Phase 1b/2a part of its RESOLVE trial testing EP-104GI in eosinophilic esophagitis.
At 12 weeks, patients on the highest dose (8mg/site, 20 sites, n=3) showed near-complete normalization of tissue health, with EoEHSS Grade improving 94% and Stage 97%. At 36 weeks, patients receiving 4mg/site (n=9) maintained the tissue gains first seen at week 12, and a clear dose-response was observed across dose levels.
Among patients with at least 60% of their esophagus treated, 58% achieved clinical remission at 12 weeks, 79% maintained remission at 24 weeks, and 67% maintained remission at 52 weeks. Across more than 200 patient-months of follow-up in 31 patients, EP-104GI was well tolerated, with no serious adverse events and no cases of oral candidiasis reported.
Eupraxia Pharmaceuticals Inc. submitted a Form 6-K as a foreign private issuer for November 2025. The report furnishes consolidated financial statements and management’s discussion and analysis for the three and nine months ended September 30, 2025, along with a November 4, 2025 press release.
The filing also includes interim certification forms signed by the Chief Executive Officer and Chief Financial Officer, and incorporates the attached financial statements and MD&A by reference into the company’s existing Form F-10 and Form S-8 registration statements.
Amendment No. 1 to a Schedule 13D reports that Joseph S. Freedman increased his beneficial stake in Eupraxia Pharmaceuticals Inc. (EPRX) by purchasing 543,130 common shares in an underwritten public offering at $5.50 per share, for an aggregate purchase price of $2,987,215 paid from his personal funds. The filing shows the Reporting Person now beneficially owns 5,533,215 shares (including common shares, preferred-share equivalents, options and warrants), representing 10.2% of the issuer's diluted common-equivalent share count based on the issuer’s reported outstanding shares.
The amendment discloses a customary 90-day lock-up agreement with the offering underwriters restricting transfers, and option agreements granting certain consultants the ability to purchase 60,000 common shares from shares beneficially owned by the Reporting Person. No other transactions in the prior 60 days were reported.
Eupraxia Pharmaceuticals is offering common shares and other securities under a shelf prospectus for aggregate proceeds up to US$200.0 million. The supplement describes an at-the-market/underwritten offering with per-share pricing shown at US$5.50 and related totals (e.g., US$70,000,001.50 and US$65,100,001.39 depending on options). Proceeds are allocated to clinical development, scale-up and corporate purposes, with explicit estimated line items including US$28.4 million, US$5.0 million, US$7.1 million and US$3.4 million. The company is developing EP-104 family products: EP-104IAR (knee OA) and EP-104GI (EoE), with ongoing Phase 1b/2a and Phase 2/Phase 3 planning and FDA interactions described. The prospectus details securities, dilution mechanics, tax and PFIC considerations for U.S. holders, risks including regulatory, clinical trial, funding and commercialization uncertainties, and potential reliance on partners and CROs.
Eupraxia Pharmaceuticals is offering common shares and other securities under a shelf prospectus for aggregate proceeds up to US$200.0 million. The supplement describes an at-the-market/underwritten offering with per-share pricing shown at US$5.50 and related totals (e.g., US$70,000,001.50 and US$65,100,001.39 depending on options). Proceeds are allocated to clinical development, scale-up and corporate purposes, with explicit estimated line items including US$28.4 million, US$5.0 million, US$7.1 million and US$3.4 million. The company is developing EP-104 family products: EP-104IAR (knee OA) and EP-104GI (EoE), with ongoing Phase 1b/2a and Phase 2/Phase 3 planning and FDA interactions described. The prospectus details securities, dilution mechanics, tax and PFIC considerations for U.S. holders, risks including regulatory, clinical trial, funding and commercialization uncertainties, and potential reliance on partners and CROs.